Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.

Trial Profile

Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-sensitive, HER-2 Negative Operable Breast Cancer. A Double Blind Randomized Phase II Study With Biomarker Evaluation.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2016

At a glance

  • Drugs Lapatinib (Primary) ; Letrozole
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms LET-LOB
  • Most Recent Events

    • 04 Jun 2013 Biomarker results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jul 2011 Preliminary results have been reported at ASCO 2011.
    • 01 Apr 2011 Primary endpoint 'Objective-clinical-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top